Citation, commencement and extent

1. —(1) These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 and come into force on 31st May 2017.

(2) These Regulations extend to England and Wales and Scotland.

Amendment of the Misuse of Drugs Regulations 2001

2.The Misuse of Drugs Regulations 2001( 2 ) are amended as follows.

3. In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16 , 18, 19, 20, 23, 26 and 27)—

(a) before “Bufotenine” insert—

• “ Adinazolam (1-(8-Chloro-6-phenyl-4 H -[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)- N,N -dimethylmethanamine)

• N -Benzyl-ethylphenidate

• Bromazolam (8-bromo-1-methyl-6-phenyl-4 H -[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) ” ;

(b) after “Cathinone” insert—

• “ 4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2 H -1,4-benzodiazepin-2-one)

• Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4 H -[1,2,4]triazolo[4,3-a][1,4] benzodiazepine) ” ;

(c) after “Concentrate of poppy-straw” insert—

• “ Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6 H -thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

• 3,4-Dichloroethylphenidate

• 3,4-Dichloromethylphenidate (3,4-DCMP)

• Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2 H -1,4-benzodiazepin-2-one) ” ;

(d) after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—

• “ Ethylnaphthidate

• Ethylphenidate ” ;

(e) after “Eticyclidine” insert—

• “ Etizolam ” ;

(f) after “Etryptamine” insert—

• “ Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2 H -1,4-benzodiazepin-2-one)

• Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4 H -[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

• 4-Fluoroethylphenidate

• 4-Fluoromethylphenidate

• Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2 H -1,4-benzodiazepin-2-one) ” ;

(g) after “9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[ c ]chromen-1-ol” insert—

• “ 3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2 H -1,4-benzodiazepin-2-one)

• Isopropylphenidate (IPP or IPPD) ” ;

(h) after “Lysergide and other N -alkyl derivatives of lysergamide” insert—

• “ Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2 H -1,4-benzodiazepin-2-one) ” ;

(i) after “Methcathinone” insert—

• “ 4-Methylmethylphenidate

• Methylmorphenate

• Methylnaphthidate (HDMP-28)

• Metizolam (4-(2-Chlorophenyl)-2-ethyl-6 H -thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

• Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2 H -1,4-benzodiazepin-2- one)

• Nitrazolam (1-Methyl-8-nitro-6-phenyl-4 H -[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• Propylphenidate ” ;

(j) after “Psilocin” insert—

• “ Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4 H -[1,2,4]triazolo[4,3-a][1,4] benzodiazepine) ” ;

(k) after “3,4-dichloro- N -[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—

• “ 3,4-dichloro- N -[2-(dimethylamino)cyclohexyl]- N -methylbenzamide (U-47,700) ” .